TAmiRNA receives SME Instrument Phase I Funding

TAmiRNA announces successful application for SME Instrument Phase I funding for its OsteomiR biomarker development program. The OsteomiR biomarker is a combination of blood circulating microRNAs that are highly correlated to fracture risk in postmenopausal women. In the near future, this biomarker will be used to diagnose risk of osteoporotic fractures early enough to enable preventive therapeutic treatment and to monitor treatment response rates in patients undergoing anti-osteoporotic therapy.

As part of the 6-month SME Instrument project, TAmiRNA will partner with the Institute for Pharmaeconomic Research in Vienna (www.ipf-ac.at) to develop a health economic model, which will allow a precise estimation of the socio-economic benefit that can be obtained by introducing the OsteomiR test into the daily routine of osteoporosis risk assessment. In addition, TAmiRNA will identify partners for assay development and manufacturing to prepare for the launch of the research-use test kit and clinical utility studies.

About the purpose of the Horizon 2020 dedicated SME Instrument “PHC-12”:
This program addresses the challenge that only few novel biomarkers are validated for use in a clinical research setting. Such validation implies the demonstration of a link to a pertinent clinical endpoint or process, as well as a robust and appropriate analytical method. Therefore, the clinical validation of biomarkers will be increasingly important for the development of new diagnostics, and this is a research area where many small European companies are active.

More information:
http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2558-phc-12- 2015-1.html

TAmiRNA GmbH is a biopharmaceutical R&D company founded to drive the discovery and development of microRNAs (miRNAs) as tools for diagnosis and treatment of age-associated disorders such as Osteoporosis, Cardiovascular Disease and Neurodegenerative Disease. TAmiRNA targets to improve patient stability and quality of life with increasing age, by providing solutions for early risk assessment of disease and combined therapeutic treatment solutions.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.